Netarsudil ophthalmic

Netarsudil ophthalmic is a prescription medication used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

• Netarsudil ophthalmic is available under the following different brand names: Rhopressa 

Common side effects of Netarsudil ophthalmic include:

• Eye redness, and
• Eye pain after using the drops

Serious side effects of Netarsudil ophthalmic include:

• Hives,
• Difficulty breathing,
• Swelling of the face, lips, tongue, or throat,
• Eye swelling,
• Redness of the eye,
• Severe discomfort in the eye,
• Crusting or drainage from the eye,
• Red, swollen, or itchy eyelids,
• Vision changes, and
• Severe burning, stinging, or irritation after using this medicine

Rare side effects of Netarsudil ophthalmic include:

• None

Seek medical care or call 911 at once if you have the following serious side effects:

• Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors;
• Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
• Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, lightheadedness, or passing out.

This is not a complete list of side effects and other serious side effects or health problems that may occur because of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

Adult Dosing

Ophthalmic solution

• 0.02% (0.2mg/mL)
• Elevated Intraocular Pressure

Adult dosage

• Instill 1 drop in the affected eye(s) once a day in the evening

Dosage Considerations – Should be Given as Follows: 

• See “Dosages”

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider, or pharmacist first

• Netarsudil ophthalmic has no noted severe interactions with any other drugs.
• Netarsudil ophthalmic has no noted serious interactions with any other drugs.
• Netarsudil ophthalmic has no noted moderate interactions with any other drugs.
• Netarsudil ophthalmic has no noted minor interactions with any other drugs.

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist about all your products. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your healthcare professional or doctor for additional medical advice, or if you have health questions or concerns.

Contraindications

• None

Effects of drug abuse

• None

Short-Term Effects

• See “What Are Side Effects Associated with Using Netarsudil ophthalmic?”

Long-Term Effects

• See “What Are Side Effects Associated with Using Netarsudil ophthalmic?”

Cautions

• Bacterial keratitis associated with the h use of multiple-dose containers of topical ophthalmic products; containers had been inadvertently contaminated by patients who had a concurrent corneal disease or a disruption of the ocular epithelial surface
• Remove contact lenses before instilling ophthalmic solution; may reinsert lenses 15 minutes following administration
• Instruct patients to avoid allowing the tip of dispensing container to do with contact with the eye, surrounding structures, fingers, or any other surface to minimize contamination of the solution; serious damage to the eye and subsequent loss of vision may result from using contaminated solutions
• Advise patients that if they develop an intercurrent ocular condition (. g, trauma, or infection), have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physician’s advice concerning the continued use of this drug

Pregnancy and Lactation

• Data are not available on use in pregnant women to inform of any drug-associated risk; however, systemic exposure to netarsudil from ocular administration is low
• IV administration of netarsudil to pregnant rats and rabbits during organogenesis did not produce adverse embryo-fetal effects at clinically relevant systemic exposures

Lactation

• No data on the presence in human milk, the effects on the breastfed infant, or the effects on milk production
• Systemic exposure to netarsudil following topical ocular administration is low, and unknown whether measurable levels of netarsudil would be present in maternal milk following topical ocular administration